CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Get Free Report) shot up 6.5% during mid-day trading on Wednesday . The stock traded as high as $0.12 and last traded at $0.12. 13,369,292 shares traded hands during trading, an increase of 139% from the average session volume of 5,602,099 shares. The stock had previously closed at $0.11.
Analyst Ratings Changes
Separately, Maxim Group upgraded shares of CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research report on Tuesday, September 10th.
Read Our Latest Stock Report on CNSP
CNS Pharmaceuticals Price Performance
CNS Pharmaceuticals Company Profile
CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.
Featured Articles
- Five stocks we like better than CNS Pharmaceuticals
- Using the MarketBeat Dividend Tax Calculator
- Work and Play: Investing in the Rise of Bleisure Travel
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
